C-type natriuretic peptide: the heart’s guardian angel

por Sangaralingham, S Jeson, Chen, Yang, Burnett, John C
Publicado 2020

Natriuretic peptide pathways in heart failure: further therapeutic possibilities

por Sangaralingham, S Jeson, Kuhn, Michaela, Cannone, Valentina, Chen, Horng H, Burnett, John C
Publicado 2022

A novel designer natriuretic peptide CD-NP suppresses TGF-beta 1 induced collagen Type I production in human cardiac fibroblasts

por Ichiki, Tomoko, Huntley, Brenda K, Sangaralingham, S Jeson, Chen, Horng H, Burnett, John C
Publicado 2009

Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling

por Ichiki, Tomoko, Huntley, Brenda K., Harty, Gail J., Sangaralingham, S. Jeson, Burnett, John C.
Publicado 2017

M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics

por McKie, Paul M, Cataliotti, Alessandro, Ichiki, Tomoko, Sangaralingham, S Jeson, Chen, Horng H, Burnett, John C
Publicado 2013

M‐Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics

por McKie, Paul M., Cataliotti, Alessandro, Ichiki, Tomoko, Sangaralingham, S. Jeson, Chen, Horng H., Burnett, John C.
Publicado 2014

Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4‐Year Follow‐Up

por Buglioni, Alessia, Cannone, Valentina, Sangaralingham, S. Jeson, Heublein, Denise M., Scott, Christopher G., Bailey, Kent R., Rodeheffer, Richard J., Sarzani, Riccardo, Burnett, John C.
Publicado 2015

A biodegradable in-situ polymer precipitation delivery system for sustained delivery of a novel chimeric natriuretic peptide CD-NP in an experimental model of myocardial infarction

por Lim, Soo Ghim, Sangaralingham, S Jeson, Ameenuddin, Syed, Martin, Fernando L, Ng, Xu Wen, Huang, Ying Ying, Venkatraman, Subbu S, Burnett, John C, Chen, Horng H
Publicado 2013

Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker

por Tan, Nicholas Y., Deng, Yihong, Yao, Xiaoxi, Sangaralingham, Lindsey R., Shah, Nilay D., Rule, Andrew D., Burnett, John C., Dunlay, Shannon M., Sangaralingham, S. Jeson
Publicado 2021

CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart

por Martin, Fernando L., Sangaralingham, S. Jeson, Huntley, Brenda K., McKie, Paul M., Ichiki, Tomoko, Chen, Horng H., Korinek, Josef, Harders, Gerald E., Burnett, John C.
Publicado 2012

A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure

por Kawakami, Rika, Lee, Candace Y.W., Scott, Christopher, Bailey, Kent R., Schirger, John A., Chen, Horng H., Benike, Sherry L., Cannone, Valentina, Martin, Fernando L., Sangaralingham, S. Jeson, Ichiki, Tomoko, Burnett, John C.
Publicado 2018

EVIDENCE FOR ANGIOTENSIN II AS A NATURALLY EXISTING SUPPRESSOR FOR THE NATRIURETIC PEPTIDE SYSTEM

por Ma, Xiao, Iyer, Seethalakshmi R., Ma, Xiaoyu, Reginauld, Shawn H., Chen, Yang, Pan, Shuchong, Zheng, Ye, Moroni, Dante, Yu, Yue, Zhang, Lianwen, Cannone, Valentina, Chen, Horng H., Ferrario, Carlos M., Sangaralingham, S. Jeson, Burnett, John C.
Publicado 2023

Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation

por Ma, Xiao, Iyer, Seethalakshmi R., Ma, Xiaoyu, Reginauld, Shawn H., Chen, Yang, Pan, Shuchong, Zheng, Ye, Moroni, Dante G., Yu, Yue, Zhang, Lianwen, Cannone, Valentina, Chen, Horng H., Ferrario, Carlos M., Sangaralingham, S. Jeson, Burnett, John C.
Publicado 2023